Clinical hepatitis after transplantation of hepatitis C virus-positive kidneys: HLA-DR3 as a risk factor for the development of posttransplant hepatitis

Transplantation

Volumn 62, Issue 12, 1996, Pages 1758-1762

  Kirk, Allan D ^a,b   Heisey, Dennis M ^a   D'Alessandro, Anthony M ^a   Knechtle, Stuart J ^a   Odorico, Jon S ^a   Rayhill, Stephen C ^a   Sollinger, Hans W ^a   Pirsch, John D ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CADAVER KIDNEY; CONFERENCE PAPER; HEPATITIS; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INFECTION RISK; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL;

ALLELES; HEPACIVIRUS; HEPATITIS; HEPATITIS C; HLA-DR3 ANTIGEN; HLA-DR4 ANTIGEN; HLA-DR5 ANTIGEN; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; RISK FACTORS;

EID: 0030461045     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199612270-00011     Document Type: Conference Paper

References (32)

1. Pereira BJG, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med 1991; 325: 454.
2. Pereira BJG, Milford EL, Kirkman RL, et al. Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med 1992; 327: 910.
3. Diethelm AG, Roth D, Ferguson RM, et al. Transmission of HCV by organ transplantation (letter). N Engl J Med 1992; 326: 410.
4. Pirsch JD, Belzer FO. Transmission of HCV by organ transplantation ]letter[. N Engl J Med 1992; 326: 412.
5. Brillanti S, Foli M, Gaiani S, et al. Persistent hepatitis C viraemia without liver disease. Lancet 1993; 341: 464.
6. Alberti A, Morsica G, Chemello L, et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340: 697.
7. Lau JYN, Davis GL. Managing chronic hepatitis C virus infection. Br Med J 1993; 306: 469.
8. Peterson MJ, Hourani MR, Major GH. HLA antigens and hepatitis B virus. N Engl J Med 1977; 297: 1124.
9. Opelz G, Vogten AJM, Summerskill WHJ, Schalm SW, Terasaki PI. HLA determinants in chronic active liver disease: possible relation of HLA-DRw3 to prognosis. Tissue Antigens 1977; 9: 36.
10. Williams RM, Martin S, Falchuk KR, et al. Increased frequency of HLA-DRw4 in chronic active hepatitis. Vox Sang 1978; 35: 366.
11. Mackay IR, Tait BD. HLA associations with autoimmune-type chronic active hepatitis: identification of B8-DRw3 haplotype by family studies. Gastroenterology 1980; 79: 1980.
12. Donaldson PT, Doherty DG, Hayllar KM, et al. Susceptibility of autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991; 13: 701.
13. Hodges S, Lobo-Yeo A, Donaldson P, Tanner MS, Vergani D. Autoimmune chronic active hepatitis in a family. Gut 1991; 32: 299.
14. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of human leukocyte antigens DR3 and DR4 in chronic viral hepatitis. Dig Dis Sci 1995; 40: 2098.
15. Koziel MJ, Dudley D, Afdhal N, et al. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol 1993; 67: 7522.
16. Shari M, Okada H, Nishioka M, et al. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol 1994; 68: 3334.
17. Jung MC, Diepolder HM, Pape GR. T cell recognition of hepatitis B and C antigens. Euro J Clin Invest 1994; 24: 641.
18. Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic predisposition of non-response to hepatitis B vaccine. N Engl J Med 1989; 321: 708.
19. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993; 105: 1502.
20. Bukh J, Purcell RH, Miller RH. Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay. Proc Natl Acad Sci USA 1992; 89: 187.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.
22. Bishop YMM, Fienberg SE, Holland PW. Discrete multivariate analysis: theory and practice. Cambridge, MA: MIT Press, 1976.
23. Berry DA. Subgroup analysis. Biometrics 1990; 46: 1227.
24. Peano G, Menardi G, Ponzetto A, Fenoglio LM. HLA-DR5 antigen: a genetic factor influencing the outcome of hepatitis C virus infection? Arch Intern Med 1994; 154: 2733.
25. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362.
26. Verdon R, Pol S, Landais P, et al. Absence of association between HLA antigens and chronicity of viral hepatitis in haemodialyzed patients. J Hepatol 1994; 21: 388.
27. Rapaport FT, Anaise D. Organ donation-1990. Transplant Proc 1991; 23: 899.
28. Okada S-I, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal region of the E2/ NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 1992; 16: 619.
29. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815.
30. Gonzalez-Peralta RP, Davis GL, Lau JYN. Pathogenic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. J Hepatol 1994; 21: 255.
31. Magrin S, Craxi A, Fabiano C, et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid therapy. Hepatology 1994; 19: 273.
32. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088.